Humacyte, Inc. — Director's Dealing 2022

Apr 5, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2022-04-04

Reporting Person: Parikh Shamik J (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-04-04	Stock Options (right to buy)	$6.9	A	144927	Acquired	2032-04-04	Common Stock (144927.0)	Direct

Footnotes

F1: The first 25% of the option becomes exercisable on April 4, 2023, after which 1/48 of the option will become exercisable on the 4th of each month through August 4, 2026.